Lv1
40 积分 2021-05-12 加入
TL1A inhibition for inflammatory bowel disease treatment: From inflammation to fibrosis
16小时前
已完结
Inflammatory bowel disease and the eye
15天前
已完结
Epidemiology and risk factors for IBD
19天前
已完结
IBD disease-modifying therapies: insights from emerging therapeutics
19天前
已完结
Inflammatory bowel disease
19天前
已完结
Advances in local drug delivery technologies for improved rheumatoid arthritis therapy
19天前
已完结
The IBD interactome: an integrated view of aetiology, pathogenesis and therapy
20天前
已完结
The physiology of prostaglandins
20天前
已完结
Investigating Drivers for M1 Muscarinic Acetylcholine Receptor‐Mediated Adverse Events by M1 Positive Allosteric Modulators
21天前
已关闭
ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension
21天前
已完结
皖公网安备34019202002308
